This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Tech Bubble 2.0 + Inflation Tsunami: How to Play Them Now
by Kevin Cook
Morgan Stanley warns investors 15% correction coming as market overvalued like dot-com days.
A Comprehensive Guide to Genomic ETFs
by Sweta Jaiswal, FRM
Genomic ETFs are expected to benefit from the favorable trends in the genomic editing space.
Genomics ETFs Surge on a Major Breakthrough in CRISPR Study
by Sweta Jaiswal, FRM
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
Top-Performing Biotech ETFs of Last Week
by Sweta Killa
Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.
Ride the Renewed Meme Stock Wave With This New ETF
by Sweta Killa
Meme stocks are those that grabbed immense investor interest due to hype on social media and online forums like Reddit, WallStreetBets and Robinhood, rather than the company fundamentals, resulting in a surge in volumes and share price.
Likely Capital Gain Tax Hike a Buying Point for These ETFs?
by Sanghamitra Saha
President Joe Biden wants to raise capital gains tax to 39.6% from the current rate of 20% for those earning $1 million or more. Since the group is just 0.3% of total population, don't expect a severe market crash over the long term.
Go Digital With This New ETF (DAPP) From VanEck
by Sweta Killa
VanEck Vectors Digital Transformation ETF (DAPP) offers a pure-play exposure to the companies powering the digital shift of the world economy.
Thematic Investing on the Rise: ARK ETFs Leading the Pack
by Sweta Killa
Thematic ETFs saw net inflows of $42.6 billion in the first two months of this year, more than three times the $13.3 billion garnered in the same period last year.
Bear of the Day: CRISPR Therapeutics (CRSP)
by Kevin Cook
Gene editors got a big boost recently from sickle cell potential and Cathie Wood's thematic investing
Ark Invest ETFs Power Active Investing Growth
by Sweta Killa
Active ETFs pulled in a record of more than $55 billion capital last year and $17.5 billion so far this year, bringing their AUM to $200 billion.
6 Hot ETFs That Could be Investors' Darling in February
by Sweta Killa
A few ETFs have garnered solid investors' interest to start a New Year and will continue to be their darlings in the month of love.
Bear of the Day: Illumina (ILMN)
by Kevin Cook
Maker of premier next-gen genomic sequencing technology lowers guidance but shares make new highs
A Deep Dive into ARK ETFs
by Neena Mishra
We highlight the best performing ETFs managed by Cathie Wood
Space ETFs Soar on ARK Investment Management's Filing
by Sanghamitra Saha
Procure Space ETF (UFO) jumped 5.7% on Jan 14 as Cathie Wood's ARK Investment Management filed for a space ETF.
Power-packed ETFs for Your Portfolio in 2021
by Sweta Killa
We have highlighted a pack of ETFs that are poised to outperform in 2021.
5 Top-Performing ARK ETFs Worth Your Attention Now
by Sweta Jaiswal, FRM
Here we highlight some ETFs from the house of ARK Investment Management that have gained more than 100% in the past year for our investors to consider.
A Guide to Biotech ETF Investing Amid the Coronavirus Crisis
by Sweta Jaiswal, FRM
The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.
ETF Market Outlook & Picks for 2021
by Neena Mishra
Two ETF experts share their market outlook and top picks for 2021.
Top Performing ETF Areas of 2020
by Neena Mishra
We highlight some ETFs that more than doubled in 2020
4 Best Performing Sector ETFs of December
by Sweta Killa
Despite the surge in coronavirus cases, December has been kind for the U.S. stock market with the major indices enjoying a historic rally.
Top & Flop Zones of 2020 and Their ETFs
by Sweta Killa
We have highlighted the best and worst-performing zones and their ETFs in 2020.
Top-Performing Biotech ETFs Amid the COVID-19 Crisis
by Sweta Jaiswal, FRM
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
4 Best Investing Areas of Q4 & Their Top ETFs
by Sanghamitra Saha
Despite yearlong COVID-19 fears, Wall Street is ending the fourth quarter on a sweet note.
5 Sector ETFs That Beat the Market in 2020
by Sweta Killa
With historic twists and turns, 2020 has turned out to be a banner year.
Top ETF Stories of 2020 & Picks for 2021
by Neena Mishra
We discuss the 2020 trends and outlook for 2021...